Understanding the barriers to, and facilitators of, ovarian toxicity assessment in breast cancer clinical trials-Reference-Cited by-同舟云学术

Understanding the barriers to, and facilitators of, ovarian toxicity assessment in breast cancer clinical trials

Published:2022-08 Issue: Volume:64 Page:56-62
ISSN:0960-9776
Container-title:The Breast
language:en
Short-container-title:The Breast

Author:

Cui Wanyuan,Phillips Kelly-Anne,Francis Prudence A.,Anderson Richard A.,Partridge Ann H.,Loi Sherene,Loibl Sibylle,Keogh Louise^ORCID

Publisher

Elsevier BV

Subject

General Medicine,Surgery

Reference43 articles.

1. Menopausal symptoms in women undergoing chemotherapy-induced and natural menopause: a prospective controlled study;Mar Fan;Ann Oncol,2010

2. Ovarian failure after adjuvant chemotherapy is associated with rapid bone loss in women with early-stage breast cancer;Shapiro;J Clin Oncol,2001

3. ESHRE Guideline: management of women with premature ovarian insufficiency;Webber;Hum Reprod,2016

4. Incidence and survival among young women with stage I-iii breast cancer: SEER 2000-2015;Thomas;JNCI Cancer Spectr,2019

5. National Cancer Institute. Surveillance, Epidemiology, and End Results Program. Cancer Stat Facts: Female Breast Cancer 2021. https://seer.cancer.gov/statfacts/html/breast.html. Access date 25 Jul 2021.

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Onset and resolution of ovarian toxicity with nirogacestat treatment in females with desmoid tumors: Updated safety analyses from the DeFi phase 3 study;Cancer;2024-05-04

2. Measuring ovarian toxicity in clinical trials: an American Society of Clinical Oncology research statement;The Lancet Oncology;2023-10

3. Cancer Treatment-Related Ovarian Dysfunction in Women of Childbearing Potential: Management and Fertility Preservation Options;Journal of Clinical Oncology;2023-04-20